Publications & Presentations

Peer-reviewed papers, white papers, books, and selected conference presentations from IDSWG members and sub-teams.

Under Construction. This page is being reviewed and expanded. The publication and presentation listings are still being verified for accuracy and completeness, and should be treated as provisional until this notice is removed.

2023–2025 2019–2022 2016–2018 White Papers Books & Chapters Abstracts & Presentations

2023–2025

  • 2025
    Wang C, Di J, Ghadessi M, Tang R, Mulatya C, Shi D, Xu T, Wang W, Mei C, Wang S, McComb B, Beckman RA, McMillan G. Insights on clinical development of cell and gene therapy for rare diseases: by DahShu Innovative Design Scientific Working Group (IDSWG). Therapeutic Innovation and Regulatory Science, 59: 1336–1355 (2025). doi:10.1007/s43441-025-00853-4
  • 2025
    Wu Y, Lu C, Aregay M et al. Company sponsored platform trials: recommendations and lessons learned from cross-industry interviews. Therapeutic Innovation and Regulatory Science, 60(1) (2026). doi:10.1007/s43441-025-00792-0
  • 2025
    Beckman RA. Basket trials (stat08485). In: Hougaard P, ed. Wiley StatsRef: Statistics Reference Online. Wiley Online Library (2025).
  • 2024
    Singh P, Sverdlov O, Beckman RA, Burden A. Integrating sustainability pillars into trial design decision-making: results of an international survey. Clinical and Translational Science, 18:5 (2024).
  • 2024
    Lu C*, Beckman RA*, Li X, Zhang W, Jiang Q, Marchenko O, Sun Z, Tian H, Ye J, Yuan S, Yung G, on behalf of the Master Protocol subteam of the Statistical Methods in Oncology Scientific Working Group, ASA Biopharmaceutical Section. (*co-first authors) Tumor agnostic approvals: insights and practical considerations. Clinical Cancer Research, 30: 480–488 (2024).
  • 2023
    Ghadessi M, Di J, Wang C, Toyoizumi K, Shao N, Mei C, Demanuele C, Tang R, McMillan G, Beckman RA. Decentralized clinical trials and rare diseases: A Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. Orphanet Journal of Rare Diseases, 18: 1–11 (2023). doi:10.1186/s13023-023-02693-7
  • 2023
    Xu H, Liu Y, Beckman RA. Adaptive endpoint selection with application in rare disease. Statistics in Biopharmaceutical Research, 16: 55–63 (2023).
  • 2023
    Huml RA, Collyar D, Antonijevic Z, Beckman RA, Quek R, Ye J. Aiding the adoption of master protocols by optimizing patient engagement. Therapeutic Innovation and Regulatory Science, 57: 1136–1147 (2023).
  • 2023
    Singh P, Burden A, Natanegara F, Beckman RA. Design and execution of sustainable decentralized clinical trials. Clinical Pharmacology and Therapeutics, 114: 802–809 (2023).
  • 2023
    Beckman RA, Collyar D, Cooner F, Haggstrom J, Niewczas J, Lu C, Mo M, Spann ME, Wathen K, Ye J. ASA BIOP section newsletter on ASA DahShu IDSWG Multidisciplinary Master Protocol Working Group. American Statistical Association Biopharmaceutical Section Newsletter, 30(2): 50–52 (2023).

2019–2022

  • 2022
    Gould AL, Campbell RK, Loewy JW, Beckman RA, Dey J, Schiel A, Burman CF, Zhou J, Antonijevic Z, Miller ER, Tang R. A framework for assessing the impact of Accelerated Approval. PLoS One, doi:10.1371/journal.pone.0265712 (2022).
  • 2022
    Beckman RA, Antonijevic Z, Ghadessi M, Xu H, Chen C, Liu Y, Tang R. Innovations in clinical development in rare diseases of children and adults: small populations and/or small patients. Pediatric Drugs (Paediatr Drugs), 24(6): 657–669 (2022). doi:10.1007/s40272-022-00538-7
  • 2022
    Beckman RA, Natanegara F, Singh P, Cooner F, Antonijevic Z, Liu Y, Mayer C, Price KL, Tang R, Xia A, Apostolaros M, Granville C, Michaels D. Advancing innovative clinical trials to efficiently deliver medicines to patients. Nature Reviews Drug Discovery, 21: 543–544 (2022).
  • 2022
    Tang R, Zhu J, Chen TT, Liu F, Jiang X, Huang B, Lee JJ, Beckman RA. Impact of Covid-19 pandemic on oncology clinical trial design, data collection, and analysis. Contemporary Clinical Trials, 116: 106736 (2022).
  • 2022
    He L, Ren Y, Chen H, Guinn D, Parashar D, Chen C, Yuan SS, Korostyshevskiy V, Beckman RA. Efficiency of a randomized confirmatory basket trial design constrained to control the family-wise error rate by indication. Statistical Methods in Medical Research, 31: 1207–1223 (2022).
  • 2022
    McMillan G, Mayer C, Tang R, Lu Y, LaVange L, Antonijevic Z, Beckman RA. Planning for the next pandemic: ethics and innovation today for improved clinical trials tomorrow. Statistics in Biopharmaceutical Research, 14: 22–27 (2022).
  • 2021
    Chen C, Zhou H, Li W, Beckman RA. How many cohorts should be considered in an exploratory master protocol? Statistics in Biopharmaceutical Research, 13: 280–285 (2021).
  • 2020
    Ghadessi M, Tang R, Zhou J, Liu R, Wang C, Toyoizumi K, Mei C, Zhang L, Deng CQ, Beckman RA. A roadmap to using historical controls in clinical trials, by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet Journal of Rare Diseases, 15:69 (2020). doi:10.1186/s13023-020-1332-x
  • 2020
    He L, Du L, Antonijevic Z, Posch M, Korostyshevskiy V, Beckman RA. Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios. Statistical Methods in Medical Research, 30: 396–410 (2020).
  • 2019
    Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M. Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 28(7): 2096–2111 (2019). doi:10.1177/0962280217747312
  • 2019
    Li W, Zhao J, Li X, Chen C, Beckman RA. Multi-stage enrichment designs and basket trial design with population selection. Statistics in Medicine, 38: 5470–5485 (2019).

2016–2018

  • 2018
    Chen C, Li X, Li W, Beckman RA. Adaptive expansions of biomarker populations in Phase 3 clinical trials. Contemporary Clinical Trials, 71: 181–185 (2018).
  • 2017
    Shentu Y, Chen C, Pang L, Beckman RA. Auto-adaptive alpha allocation: a strategy to mitigate risk on study assumptions. Statistics in Biosciences, 1–15 (2017).
  • 2017
    Li W, Chen C, Li X, Beckman RA. Estimation of treatment effect in two-stage confirmatory trials of personalized medicines. Statistics in Medicine, 36: 1843–1861 (2017). doi:10.1002/sim.7272
  • 2017
    Chen C, Deng Q, He L, Mehrotra DV, Rubin EH, Beckman RA. How many tumor indications should be initially studied in clinical development of next generation immunotherapies? Contemporary Clinical Trials, 59: 113–117 (2017).
  • 2016
    Beckman RA, Antonijevic Z, Kalamegham R, Chen C. Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker. Clinical Pharmacology and Therapeutics, 100: 617–625 (2016).
  • 2016
    Trusheim M, Shrier AA, Antonijevic Z, Beckman RA, Campbell R, Chen C, Flaherty K, Loewy J, Lacombe D, Madhavan S, Selker H, Esserman L. PIPELINEs: creating comparable clinical knowledge efficiently by linking trial platforms. Clinical Pharmacology and Therapeutics, 100: 713–729 (2016).
  • 2016
    Chen C, Beckman RA. Informational design of confirmatory Phase III trials. Biopharmaceutical Report, 23: 1–16 (2016).
  • 2016
    Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M. Optimizing trial designs for targeted therapies. PLoS One, 11(9):e0163726 (2016). doi:10.1371/journal.pone.0163726
  • 2016
    Yuan SS, Chen A, He L, Chen C, Gause CK, Beckman RA. On group sequential enrichment design for basket trial. Statistics in Biopharmaceutical Research, 8: 293–306 (2016).
  • 2016
    Chen C, Li N, Yuan S, Antonijevic Z, Kalamegham R, Beckman RA. Statistical design and considerations of a Phase 3 basket trial for simultaneous investigation of multiple tumor types in one study. Statistics in Biopharmaceutical Research, 8: 248–257 (2016).
  • 2016
    Chen C, Li N, Shentu Y, Pang L, Beckman RA. Adaptive informational design of confirmatory Phase III trials with an uncertain biomarker effect to improve the probability of success. Statistics in Biopharmaceutical Research, 8: 238–247 (2016).

White Papers & Guidance Documents

White Paper / Published

A Roadmap to Using Historical Controls in Clinical Trials

DIA-ADSWG guidance on appropriate use of historical control data in rare disease trials. Orphanet Journal of Rare Diseases, 2020.

Read paper
White Paper / Published

Decentralized Clinical Trials in Rare Diseases

DIA-IDSWG principles and practical guidance for incorporating decentralized trial elements in rare disease programs. Orphanet Journal of Rare Diseases, 2023.

Read paper
White Paper / Published

Cell and Gene Therapy for Rare Diseases

DahShu IDSWG review of clinical development considerations for cell and gene therapies in rare disease settings. Therapeutic Innovation & Regulatory Science, 2025.

Read paper
Guidance / In Preparation

Master Protocol Systematic Literature Review Update (2020–2025)

Update of the Meyer et al. (2020) systematic review. Volunteers needed for full-text review and data extraction. Contact Peter Mesenbrink.

MPWG details

Books & Book Chapters

  • 2025
    Master Protocol Clinical Trials for Evidence Generation: Strategies, Designs, Operations, and Case Studies
    Edited by Ruixiao Lu, Jingjing Ye, Chengxing (Cindy) Lu, and William Wang. Chapman & Hall/CRC Biostatistics Series (2025). ISBN 9781032544526. Multiple IDSWG members contributed chapters, including Robert A. Beckman, Cindy Lu, Kristine Broglio, Cong Chen, Philip He, Heng Zhou, Helen Zhou, Linchen He, Martin Posch, Olivier Collignon, Thomas Gwise, and others.
  • In Press
    Karnoub M, Just F, Yin J, Vlajnic V. Chapter 11: Machine Learning/Artificial Intelligence in Drug Development. In: Kundu MG, Ghosh D, eds. Statistics in Clinical Development of Cancer Drugs: Recent Trends & Advances. Springer.
  • 2022
    Platform Trials in Drug Development: Umbrella Trials and Basket Trials
    Edited by Zoran Antonijevic and Robert A. Beckman. Chapman & Hall/CRC Biostatistics Series, Taylor & Francis Group (2022).
    IDSWG contributing authors: Ohad Amit, Carl-Fredrik Burman, Cong Chen, Olivier Collignon, Valerii Fedorov, Qi Jiang, Sebastian Jobjornsson, Franz Koenig, Sergei Leonov, Janet Li, Ed Mills, Martin Posch, Satrajit Roychoudhury, Anja Schiel, Nigel Stallard, Kristian Thorlund, Sammy Yuan.
  • 2022
    Beckman RA. Basket trial design. In: Frey BB, ed. The SAGE Encyclopedia of Research Design. SAGE Publications, Thousand Oaks, California, pp 82–83 (2022).
  • 2021
    Antonijevic Z, Beckman RA, Huml J, Liu Y, Mayer C, McMillan G, Tang R. Patient benefits from innovative designs in rare diseases. In: Huml RA, ed. Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives. Springer Nature, pp 147–160 (2021).
  • 2021
    Tang R, Beckman RA, Liu Y, Xu H, Ghadessi M, Chen C, Antonijevic Z. Novel approaches to clinical trials in rare diseases. In: Huml RA, ed. Rare Disease Drug Development. Springer Nature, pp 127–146 (2021).
  • 2021
    Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives. Edited by Raymond A. Huml. Springer Nature (2021). IDSWG contributors: McMillan G, Antonijevic Z, Tang R, Liu Y, Mayer C, Beckman RA, Ghadessi M, Chen C, Xu H.
  • 2019
    Beckman RA, Chen C. Trial designs for rare diseases and small sample sizes in oncology. In: Halabi S, Michiels S, eds. Textbook of Clinical Trials in Oncology: A Statistical Perspective. Chapman & Hall/CRC Press, pp 297–316 (2019).
  • 2019
    Beckman RA, Chen C. Informational designs and potential applications to rare disease. In: Carini C, Fidock M, Van Gool A, eds. Handbook of Biomarkers and Precision Medicine. Chapman & Hall/CRC Press, pp 183–188 (2019).
  • 2018
    Beckman RA, Chen C. Basket trials at the confirmatory stage. In: Antonijevic Z, Beckman RA, eds. Platform Trials in Drug Development. Chapman & Hall/CRC Biostatistics Series (2018). [Also: Guinn D, Madhavan S, Beckman RA. Harnessing real-world data to inform platform trial design; Beckman RA et al. Decision analysis from the perspectives of single and multiple stakeholders; Chen C, Beckman RA. Control of Type I error in confirmatory basket trials, all in the same volume.]

Abstracts, Posters & Presentations

2026 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015

2026

  • Beckman RA. “Two Novel Study Designs: Randomized Confirmatory Basket Trials and Adaptive Endpoint Selection.” Invited presentation to AstraZeneca Global Statistical Forum and Washington Statistical Society, April 9, 2026.

2025

  • Wathen K. Advancing Clinical Trials with Master Protocols: Benefits, Challenges, and Key Insights. ICSA Annual Meeting, 2025.
  • Spann M. Master Protocol Clinical Trials: Regulatory Considerations and Applications. ICSA Annual Meeting, 2025.
  • Wathen K. Navigating the Complexities of Adaptive Platform Trials: Design and Simulation. JSM 2025.
  • Spann M. Master Protocols: Your Focus May Need More Focus. JSM 2025.
  • He L and Beckman RA. Randomized Confirmatory Basket Trial: Performance Evaluation in Rare Disease Using Real-World Data. American College of Rheumatology Congress, 2025.
  • Tang R. Master Protocols for Rare Disease Clinical Trials. ICSA Annual Meeting, 2025. [Slides]

2025 (IDSWG Group Presentations)

  • Beckman RA. “DahShu Innovative Design Scientific Working Group: Introduction.” Invited presentation, ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW 2025), September 21, 2025. [Download slides]
  • IDSWG members serving on RISW 2026 Steering Committee.
  • IDSWG members served on Steering and Scientific Programming Committees, International Society for Biopharmaceutical Statistics (ISBS) Meeting, Baltimore, Maryland, March 2024.

2024

  • “Platform Trials, Shaping the Regulatory Guidance for Future Innovation.” Invited panel discussion, International Society for Biopharmaceutical Statistics (ISBS) Webinar, December 6, 2024.
  • Suttner L (presenting). “Evaluation of Adaptive Endpoints Selection with Application in Rare Disease.” Joint Statistical Meetings, Portland, Oregon, August 7, 2024.
  • Beckman RA. Steering Committee and Scientific Program Committee member, ISBS Meeting, Baltimore, Maryland, March 6–9, 2024.
  • Beckman RA. Session Chair, “Investigating the Value of Digital Twins in Biopharmaceutical Research and Development.” ISBS Meeting, Baltimore, Maryland, March 9, 2024.
  • Beckman RA. “Generalized Randomized Confirmatory Basket Trials: Efficiency, Type I Error Control, and a Simulated Application.” Oral presentation, ISBS Meeting, Baltimore, Maryland, March 8, 2024.
  • Beckman RA. “Adaptive Endpoint Selection with Application to Rare Diseases.” ISBS Meeting, Baltimore, Maryland, March 8, 2024.
  • Narayana S (presenting). “Quantifying Heterogeneity in Phase III Oncology Clinical Trials.” Oral presentation, ISBS Meeting, Baltimore, Maryland, March 8, 2024.

2023

  • Beckman RA. “Innovative Clinical Trial Designs and Health Care Policy Implications.” Invited lecture, 14th Annual Dupont Summit on Science, Technology, and the Environment, Washington, DC, December 1, 2023.
  • Beckman RA. “Adaptive Endpoint Selection with Application to Rare Diseases.” Invited lecture, Office of Biostatistics, FDA Center for Drug Research and Evaluation (CDER), Silver Spring, Maryland, October 20, 2023.
  • Beckman RA. Chair, “Multidisciplinary Considerations in Master Protocol Framework.” ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (ASA-BIOP RISW 2023), Bethesda, Maryland, September 29, 2023.
  • Beckman RA. “Innovations in Clinical Development in Rare Diseases in Children and Adults.” Invited keynote presentation, Central European Network (CEN) 2023, Basel, Switzerland, September 7, 2023.
  • Beckman RA. Chair, “Decentralized Trials for Rare Diseases: What Are The Benefits and Risks?” Session, Joint Statistical Meetings, Toronto, Canada, August 9, 2023.
  • Beckman RA. “Generalized Randomized Confirmatory Basket Trials: Efficiency, Type I Error Control, and a Simulated Application.” Oral presentation, Joint Statistical Meetings, Toronto, Canada, August 8, 2023.
  • Beckman RA. “Adaptive Endpoint Selection with Application to Rare Disease.” Drug Information Association Global Annual Meeting, Boston, Massachusetts, June 28, 2023.
  • Beckman RA. “Optimizing Proof of Concept Across Oncology Portfolios Subject to Budgetary Limitations.” Oral presentation, Duke Industry Statistics Symposium, virtual, March 31, 2023.
  • Xu H (presenting). “Adaptive Endpoints Selection with Application in Rare Disease.” Oral presentation, Duke Industry Statistics Symposium, virtual, March 30, 2023.
  • He L (presenting). “Utilizing Real-World Data to Inform a Confirmatory Basket Trial Design: Studying Use of Rituximab in Autoimmune Diseases.” Oral presentation, Duke Industry Statistics Symposium, virtual, March 30, 2023.
  • Xu H (presenting). “Adaptive Endpoints Selection with Application in Rare Disease.” Bay-Area Biotech-Pharma Statistical Working Group, San Francisco, California.

2022

  • Beckman RA. “Interdisciplinary Perspective.” Invited oral presentation and panel discussion, EU-PEARL Webinar: Non-Concurrent Controls in Platform Trials, February 24, 2022. (Presented by Dr. Stephen Senn due to medical emergency.)

2021

  • Beckman RA. Co-chair of Organizing Committee and Co-chair of session “Decision Making for Master Protocols.” Drug Information Association Master Protocols and Complex Innovative Designs Conference, virtual, November 4–5, 2021.
  • Beckman RA. “Decision Analysis and Efficiency: Concepts and Application Examples.” Invited oral presentation, DIA Master Protocols and Complex Innovative Designs Conference, virtual, November 4, 2021.
  • Beckman RA. Session Chair and Panel Discussion Moderator, “Innovative Designs for Acute Leukemia: Patient, Sponsor, and Investigator Perspectives.” DIA Master Protocols and Complex Innovative Design Conference, virtual, November 5, 2021.
  • Beckman RA. “Master Protocols: Benefits for Clinical Trial Participants and Patients.” Joint Statistical Meetings, virtual, August 8–12, 2021.
  • McMillan G (presenting). “Ethical Principles in Drug Development.” Joint Statistical Meetings, virtual, August 8–12, 2021.
  • Ghadessi M (presenting). “Historical Controls in Clinical Trials.” Joint Statistical Meetings, virtual, August 8–12, 2021.
  • Xu H (presenting). “Adaptive Endpoints Selection with Application in Rare Disease.” Joint Statistical Meetings, virtual, August 8–12, 2021.
  • Beckman RA. “Clinical Trial Designs for Rare Diseases: the Informational Design and the Confirmatory Basket Trial.” Invited oral presentation, Syneos Rare Disease Consortium, virtual, July 14, 2021.
  • Beckman RA. “Master Protocols: Benefits for Clinical Trial Participants and Patients.” DIA/FDA Biostatistics Industry and Regulator Forum, virtual, April 14, 2021.

2020

  • Beckman RA. “Efficiency and Type I Error Control of a Generalized Confirmatory Basket Trial Design.” Invited oral presentation, Clinical Innovation and Supply Chain Management Conference, Informa, virtual, October 27, 2020.
  • Panel discussion. “Basket, Umbrella, and Platform Trials: Protocol Design and Trial Types: Best Practices and Lessons Learned.” Clinical Innovation and Supply Chain Management Conference, Informa, virtual, October 27, 2020.
  • Panel discussion. “Recent Innovations in Bayesian Decision-Making in Drug Development.” ASA Biopharmaceutical Section Regulatory-Industry Workshop, virtual, September 25, 2020.
  • Beckman RA. Co-chair of Organizing Committee, DIA/FDA Workshop on Advancing Complex Innovative Clinical Trial Designs to Efficiently Deliver Medicines to Patients, Silver Spring, Maryland, March 2–3, 2020. (Collaboration between IDSWG, BSWG, FDA, DIA, BIO, and PhRMA. Sessions covered the FDA pilot program, master protocols, adaptive designs, Bayesian techniques, external controls, and regulatory harmonization across the US, EU, and Japan. This collaboration resulted in a comment published in Nature Reviews Drug Discovery in 2022.)
  • Beckman RA. “Efficiency and Type I Error Control of a Generalized Confirmatory Basket Trial Design.” Invited lecture, DIA/FDA Workshop on Advancing Complex Innovative Clinical Trial Designs, Silver Spring, Maryland, March 2–3, 2020.

2019

  • Beckman RA. “Design Concept for a Confirmatory Basket Trial.” 2019 MD Anderson Cancer Center iBRIGHT Symposium, Houston, Texas, November 2019.
  • Beckman RA. “Clinical Trials Designs for Rare Diseases: The Confirmatory Basket Trial and the Informational Design.” Invited lecture, New England Rare Disease Society (NERDS) 2019 Annual Meeting, Boston, Massachusetts, October 2019.
  • Beckman RA. “Historical Controls in Clinical Trials.” Discussant (invited), 2019 International Chinese Statistical Association Applied Statistics Symposium, Raleigh, North Carolina, June 2019.

2018

  • Beckman RA. “Basket Trial Design and Implementation Considerations.” Cytel webinar, December 2018. (518 registrants, broke previous record of 414 in the 8-year history of this webinar series.)
  • Beckman RA. “Generalized Design Concept for a Confirmatory Basket Trial.” Invited lecture, Vertex Pharmaceuticals, December 2018.
  • Beckman RA. Meeting chair and keynote address: “Design Concept for a Confirmatory Basket Trial.” CBINET Basket and Umbrella Trials for Oncology, Philadelphia, Pennsylvania, October 2018.
  • Beckman RA. “Design Concept for a Confirmatory Basket Trial.” Oral presentation and panel discussion (with Richard Simon, NCI, and Rajeshwari Sridhara, FDA). FDA–ASA Biopharmaceutical Section Workshop, Washington, DC, September 2018.
  • Li N (presenting). “A Generalized Design for a Confirmatory Basket Trial.” Joint Statistical Meetings, Vancouver, British Columbia, July 30–August 2, 2018.
  • Beckman RA. “Novel Adaptive Design for a Confirmatory Basket Trial and Best Practices for Application.” Cambridge Healthtech Institute 34th Annual Biomarkers and Immuno-Oncology World Congress, Boston, Massachusetts, June 2018.

2017

  • Beckman RA. “Design Concept for a Confirmatory Basket Trial.” Invited oral presentation, European Medicines Agency Workshop on Histology-Independent Indications in Oncology, London, UK, December 2017.
  • Beckman RA. “Design Concept for a Confirmatory Basket Trial.” Invited oral presentation, Cytel East Symposium and User Group Meeting, Cambridge, Massachusetts, October 2017.
  • Beckman RA. “Maximizing the Efficiency of Proof of Concept Studies and of Arrays of Proof of Concept Studies for Multiple Drugs or Indications.” Central European Network–International Society of Biometrics and Statistics (CEN-ISBS) Conference 2017, Vienna, Austria, August 2017.
  • Beckman RA. Session chair, “Emerging Topics in the Design and Analysis of Clinical Trials,” and discussant, “Statistical Methodology for the Design and Analysis of Trials in Small Populations.” CEN-ISBS Conference 2017, Vienna, Austria, August 2017.
  • Beckman RA. “Two Novel Designs for Small Populations: the Confirmatory Basket Trial and the Informational Design.” Invited oral presentation and panel discussion, ASA Princeton-Trenton Chapter Spring Symposium, Rutgers University, Piscataway, New Jersey, May 2017.
  • Beckman RA. “A General Design for Confirmatory Basket Trials.” Invited oral presentation, InSPiRe Conference on Methodology for Clinical Trials in Small Populations and Rare Diseases, University of Warwick, Coventry, England, April 2017.

2016

  • Beckman RA. “A General Design for a Confirmatory Basket Trial.” Poster session, Innovation Center for Biomedical Informatics Annual Symposium, Georgetown University, Washington, DC, October 2016.
  • Posch M (presenting). “A Decision Theoretic Approach to Optimize Clinical Trial Designs for Targeted Therapies.” International Society for Computational Biology Annual Meeting, Orlando, Florida, July 2016.
  • Beckman RA. Session and meeting co-organizer and invited oral presenter: “Design Concept for a Confirmatory Basket Trial.” Trends and Innovations in Clinical Trial Statistics, Durham, North Carolina, May 2016.
  • Beckman RA. “A Novel Design for a Phase 3 Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker.” Cambridge Healthtech Biomarker World Congress, Philadelphia, Pennsylvania, May 2016.
  • Beckman RA. “Optimizing Trial Designs for Targeted Therapies, A Decision Theoretic Approach Comparing Sponsor and Public Health Perspectives.” 4th Joint Statistical Meeting of the Deutsche Arbeitsgemeinschaft Statistik (DAGStat 2016), Göttingen, Germany, March 2016.
  • Beckman RA. “Clinical and Statistical Considerations in Design of Basket Trials.” Drug Information Association (DIA) KOL Lecture Series, online, February 2016.

2015

  • Ondra T (presenting). “A Decision Theoretic Approach to Subgroup Selection.” Conference on Adaptive Designs and Multiple Testing Procedures, Cologne, Germany, June 2015.
  • Beckman RA. Workshop chair, “Predictive Subgroup Methodologies and Molecular Basket Designs.” 51st Annual Drug Information Association (DIA) Meeting, Washington, DC, June 2015.

Page last reviewed: